Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | HK1 | P19367 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143358 | 0.85 | CDK2 (0.57) | CYP1A2CYP2D6CYP3A4CYP2C19KMT2A | |
| SCHEMBL13101037 | 0.81 | MEN1 (0.58) | LTA4HCYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL22792284 | 0.81 | LTA4H (0.53) | LTA4HCYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL22792060 | 0.81 | LTA4H (0.53) | LTA4HCYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL22792621 | 0.81 | CYP1A2 (0.54) | LTA4HCYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL6283187 | 0.80 | MAP4K4 (0.48) | KMT2AMEN1 | |
| SCHEMBL22792331 | 0.79 | CYP1A2 (0.50) | LTA4HCYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL3552220 | 0.79 | KMT2A (0.56) | LTA4HCYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL22792252 | 0.79 | POLB (0.52) | LTA4HCYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL22792616 | 0.78 | MEN1 (0.51) | LTA4HCYP1A2CYP2D6CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252229-A2 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| EP-1704145-B1 | SELECTIVE KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2012-06-13 | — | — | EP | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| CN-100558715-C | Kinases inhibitor | CYTOPIA PTY LTD (AU) | 2009-11-11 | — | — | CN | disclosed |
| CN-100465173-C | Selective kinase inhibitors | CYTOPIA RES PTY LTD (AU) | 2009-03-04 | — | — | CN | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| EP-1513821-B1 | PROTEIN KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-10-31 | — | — | EP | disclosed |
| EP-1513821-B1 | PROTEIN KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-10-31 | — | — | EP | disclosed |
| CN-1906190-A | Selective kinase inhibitors | CYTOPIA RES PTY LTD (AU) | 2007-01-31 | — | — | CN | disclosed |
| US-7122550-B2 | Protein kinase inhibitors | CYTOPIA PTY LTD (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20060148824-A1 | Protein kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2006-07-06 | — | — | US | disclosed |
| EP-1513821-A4 | PROTEIN KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2006-05-03 | — | — | EP | disclosed |
| CN-1656082-A | Protein kinase inhibitors | CYTOPIA PTY LTD (AU) | 2005-08-17 | — | — | CN | disclosed |
| EP-1513821-A1 | PROTEIN KINASE INHIBITORS | Cytopia PTY Ltd (AU) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2004-11-25 | — | — | US | disclosed |
| WO-2003099796-A1 | PROTEIN KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | LCK, IRAK1, MAP2K5 | LTA4H 344/4885CYP1A2 1752/4885CYP2D6 1556/4885 |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | LCK, CHUK, CSK | LTA4H 2523/4885CYP1A2 2072/4885CYP2D6 828/4885 |
| US-20060148824-A1 | Protein kinase inhibitors | MAP3K20, MAP4K2, MAP3K1 | LTA4H 4578/4885CYP1A2 2405/4885CYP2D6 1992/4885 |
| US-20080207613-A1 | Selective Kinase Inhibitors | LCK, CHUK, CSK | LTA4H 2523/4885CYP1A2 2072/4885CYP2D6 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.